Abstract-The aging spontaneously hypertensive rat (SHR) is a model in which the transition from chronic stable left ventricular hypertrophy to overt heart failure can be observed. Although the mechanisms for impaired function in hypertrophied and failing cardiac muscle from the SHR have been studied, none accounts fully for the myocardial contractile abnormalities. The cardiac cytoskeleton has been implicated as a possible cause for myocardial dysfunction.
C ardiac hypertrophy is a compensatory response to a sustained mechanical stress of the heart that allows it to meet the demands of an increased workload. Although initially beneficial in terms of maintaining total pump performance, stable hypertrophy may progress to a decompensated state, with cardiac pump dysfunction 1 and myocardial depression. 2, 3 The spontaneously hypertensive rat (SHR) is a wellestablished model of genetic hypertension that leads to an increase in cardiac mass, which often initially maintains cardiac performance despite the elevation of systemic arterial pressure. Nonetheless, if the pressure overload is sustained for a sufficient period of time, cardiac failure may supervene. 4 Thus, the aging SHR is a model in which one can observe the transition from chronic stable left ventricular (LV) hypertrophy to overt heart failure.
Although the mechanisms for impaired function of failing hypertrophied cardiac muscle have been studied, none accounts fully for the contractile abnormalities of failing hypertrophied myocardium from SHR. The mechanisms that may contribute to the development of heart failure include the following: alterations in excitation-contraction coupling, intrinsic changes in contractile proteins, impaired autonomic modulation during stress, insufficient energy supply, extracellular matrix changes, and myocyte dropout. 5 The cytoskeleton is a well-organized structure that maintains the various subcellular organelles in their normal spatial arrangement and, thus, represents a scaffolding structure within the cells. 6 -8 The cytoskeleton can be classified according to the diameter of the component fibers: microfilaments or actin filaments (6 nm), intermediate filaments (10 nm) , and microtubules (25 nm).
Tsutsui et al 9 tested the hypothesis that in excess the microtubules are responsible for the contractile abnormalities of cardiocytes hypertrophying in response to a pressure overload. They analyzed the effects of colchicine on sarcomere motion in cardiocytes isolated from cats submitted to right ventricle (RV) overloading by pulmonary artery banding. Exposure of hypertrophied RV cardiocytes to colchicine normalized the initially abnormal contractile function (ie, the initially depressed shortening and velocity of shortening in RV cells improved in response to colchicine). The investigators concluded that an excess of microtubules in stresshypertrophied cells increases the resistive intracellular load on the shortening sarcomere, which impedes sarcomere motion. They suggested that the microtubules are causally involved in the contractile dysfunction of cardiocytes hypertrophying in response to a pressure overload and that the microtubules may have significance during the transition from stable compensated hypertrophy to heart failure. Subsequent studies also demonstrated the role of the cytoskeleton in the cardiomyocyte dysfunction of the pressure-overload hypertrophied RV. 10 -12 On the other hand, Bailey et al 13 showed that depolymerization of microtubules by colchicine did not cause a significant change in contraction amplitude in either normal or hypertrophied myocytes from feline ventricles. Collins et al 14 failed to show that the level of ␤-tubulin or its polymerization state affects LV function during the transition from compensated pressure-overload hypertrophy to heart failure in aorta-banded guinea pigs. In addition, our group 15 administered colchicine to SHR beginning at 12 to 13 months of age in an effort to prevent the transition to heart failure observed in the SHR. 1, 5 Chronic colchicine administration failed to prevent myocardial dysfunction or heart failure.
In the current study we investigated the direct relationship between mechanical performance and colchicine administration to myocardium from SHR that had developed myocardial dysfunction and heart failure. We hypothesized that if increased microtubules have an important role in contractile dysfunction of failing hypertrophied muscle, colchicine should promote an improvement in the isolated cardiac papillary muscle performance.
Methods

Animal Model
Male SHR and normotensive Wistar-Kyoto (WKY) control rats 18 to 23 months of age were studied. It is known that a large number of SHR demonstrate evidence of heart failure beginning at the age of 18 months. 1, [3] [4] [5] 15 When SHR developed tachypnea and labored respiration, they were studied within 1 to 2 weeks. Failure was documented at sacrifice by the presence of thoracic effusions, left atrial thrombi and right ventricular hypertrophy. 1, [3] [4] [5] 15 Left ventricular papillary muscle preparations were examined from 3 groups of rats: (1) aging SHR with evidence of heart failure (SHR-F), (2) agematched SHR without evidence of heart failure (SHR-NF), and (3) age-matched normotensive WKY rats.
Isolated Muscle Performance
Cardiac intrinsic contractile performance was evaluated by studying isolated papillary muscle from the LV as described in detail previously. 1 Briefly, at the time of study, rats were killed, and their hearts were quickly removed and placed in oxygenated KrebsHenseleit solution at 28°C. 16 The LV anterior or posterior papillary muscles were dissected free, mounted between 2 spring clips, and placed vertically in a chamber containing Krebs-Henseleit solution at 28°C and oxygenated with a mixture of 95% O 2 -5% CO 2 (pH 7.38). The muscles were stimulated at a rate of 12 contractions/min at a voltage 10% above threshold. The spring clip on the upper end of the muscle was attached to a low inertia DC pen motor (model G100-PD; General Scanning), and the lower clip to a semiconductor strain-gauge tension transducer (model DSC-3; Kistler-Morse). A digital computer with an analog-to-digital interface allowed control of either tension or length of the preparation. Tension and length data were sampled at a rate of 1 kHz and stored on disk for later analysis.
After the muscles were mounted, they were equilibrated for 30 minutes. After this period, muscles were gradually stretched to the peak of the active tension (AT) versus length curve (L max , defined as the muscle length resulting in peak AT) and equilibrated for an additional 15 minutes while performing physiologically sequenced contractions. 17 Isometric contraction parameters were determined, which included resting tension (RT, g/mm 2 ), active tension (AT, g/mm 2 , defined as peak isometric tension minus resting tension), peak rate of isometric tension development (peakϩdT/dt, g ⅐ mm Ϫ2 ⅐ s Ϫ1 ), electromechanical delay (EMD, ms; defined as the time from stimulation to the onset of tension development), time to peak tension (TPT, ms, defined as the time from the onset of tension development to the time of peak tension), maximum rate of tension decline (ϪdT/dt, g ⅐ mm Ϫ2 ⅐ s
Ϫ1
), and time from peak tension to 50% relaxation (RT 1/2 , ms). In addition, maximum velocity of isotonic shortening (V max , muscle lengths/s) was determined at L max .
Central Segment Measurements
After these baseline determinations were made, 2 central segment markers, spaced approximately 1 to 2 mm apart, were applied for central segment length determinations as described previously. 18, 19 The preparation is scanned longitudinally by a laser beam at a rate of 1000 Hz. Resolution is 1.6 m and root-mean-square noise on the order of 6.5 m, or approximately 0.4% of central segment length for a typical 2.0-mm segment.
Stress-Strain Analysis
The analysis of myocardial stiffness was based on central segment measurements, to avoid potential errors due to "damaged end" effects. Passive tension-length relationships were determined by applying length ramps to the whole papillary muscle at a rate of 1.0 mm/s, corresponding to a normalized rate of length change on the order of 0.1 muscle length/s. Because of the large deformations involved, eulerian stress (tension/instantaneous area) was used, as opposed to Lagrangian stress (tension/reference area). Central segment stress ( cs ) was defined as tension normalized by instantaneous cross-sectional area, calculated from the measured cross-sectional area assuming incompressibility:
where CSA cs(inst) is instantaneous central segment cross-sectional area, CSA cs(ref) is the cross-sectional area at the reference length, L cs(inst) is instantaneous central segment length, and L cs(ref) is the reference central segment length. Natural strain (⑀) is generally defined as ⑀ϭln (L/L 0 ), where L is length and L 0 is length at zero stress (or "slack length"). Because of the exponential nature of the stress-strain relation, and therefore the shallow slope at low loads, the determination of true slack length (as used in the traditional definition of strain) is subject to considerable experimental error. Therefore, a modified natural strain definition was used in the present study:
where L cs is instantaneous central segment length and L 0.1 is central segment length at a load of 0.1 kdyne/mm 2 . With this definition, ⑀ϭ0 at a near-slack "reference length" at which ϭ0.1 kdyne/mm 2 . If we assume that passive myocardial stress ()-strain (G) relations are exponential in nature, 20 the relation can be expressed as ϭce (k⑀) . With a log transformation, log ()ϭlog(c)ϩk⑀. Thus whole muscle stiffness, k can be determined from the slope of the log () versus ⑀ relation. The central segment stiffness constant, k cs , was derived from the slope of the log ( cs ) versus ⑀ cs relation. In the present study it was found that the relations were almost invariably well described by a single exponential.
Isometric and isotonic parameters were recorded from all muscles at the apex of the AT-length relation. Initially, the effects of colchicine 10 Ϫ6 mol/L were studied; however, no change in papillary muscle function was observed. Therefore, the 3 groups of muscles (SHR-F, SHR-NF, and WKY) were studied at colchicine concentrations of 10
Ϫ5
, 10 Ϫ4 , and 10 Ϫ3 mol/L. The contractile function of each muscle was followed over a 30-minute period (at 5, 10, 20, and 30 minutes).
LV and RV wet weight normalized by body weight (BW; LV/BW and RV/BW, respectively) were used as indexes of ventricular hypertrophy. All force data compiled during the protocol were normalized by the cross-sectional area of the muscle and V max data by the muscle length.
Tubulin Assays
Four additional SHRs were studied; 1 papillary muscle from each animal was immediately frozen in liquid nitrogen. The other muscle preparation was exposed to colchicine 10 Ϫ4 mol/L for 60 (nϭ3) or 90 (nϭ1) minutes while mechanical activity was recorded, and then tissues were immediately frozen. Subsequently, frozen muscle papillary preparations weighing 5 to 10 mg each were homogenized in microtubule stabilization buffer (50% glycerol, 5% dimethyl sulfoxide, 10 mmol/L sodium phosphate, 0.5 mmol/L MgCl 2 , 0.5 mmol/L ethylenebis [oxyethylenenitrilo] tetraacetic acid, 0.5 mmol/L GTP, and 100 U/mL aprotinin [pH 6.95]) and centrifuged at 100 000g for 15 minutes in a bench-top Beckman ultracentrifuge. The supernatant was removed and saved to analyze free tubulin. The pellet was dissolved in depolymerization buffer (0.25 mol/L sucrose, 0.5 mmol/L GTP, 0.5 mmol/L MgCl 2 , 10 mmol/L sodium phosphate, and 100 U/mL aprotinin, pH 6.95), homogenized, and incubated for 1 hour at 4°C to depolymerize the microtubules. After centrifugation, the supernatant was assayed for microtubule-derived tubulin.
Forty to 50 g protein from each fraction was separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred to nitrocellulose membranes (Schleischer and Schuell), and the membranes were stained with Ponceau S to confirm equal loading of the samples. After destaining, the membrane was incubated for 1 hour in blocking buffer (TBST; 25 mmol/L Tris [7.5] , 137 mmol/L NaCl, 2.7 mmol/L KCl, 0.2% Tween-20) containing 5% nonfat dry milk. The membrane was then incubated with anti-␤-tubulin (Sigma Chemical Co, St Louis, Mo) diluted 1:500 in blocking buffer. Following washings with TBST, the membrane was incubated with 1:10 000 dilution of peroxidaseconjugated mouse anti-goat IgG. The immune complexes were detected using a chemiluminescence kit (Du Pont-NEN)
Statistical Methods
Data are expressed as meanϮSD. Data from SHR-F were compared with those from age-matched SHR-NF and from WKY using a 1-way ANOVA with replications, and the Newman-Keuls multiple sample comparison test 21 was used to localize differences where appropriate. The comparisons of AT values obtained at each dose of colchicine (10 Ϫ5 , 10
Ϫ4
, and 10 Ϫ3 mol/L) were made by repeated measures analysis (multivariate analysisϪmean profile). The comparisons in each group (baseline versus colchicine) were performed using Student's paired t test. Differences were considered to be significant when PϽ0.05.
Results
Clinical and Pathological Data
Criteria for heart failure were based on previous findings, in which animals with evidence of heart failure had findings that included labored respiration, left atrial thrombi, pleural and pericardial effusions, and RV hypertrophy. 1, [3] [4] [5] 15 Animals in the SHR-F group were studied when they exhibited tachypnea and labored respiration. In this group, 6 of 6 animals all had pleural and/or pericardial effusions and RV hypertrophy (RV/BWՆ0.80), and 5 had left atrial thrombi. None of the animals in the SHR-NF and WKY groups exhibited any of these clinical or pathological features.
Biometric and tissue wet-to-dry weight ratio data for SHR-F, SHR-NF, and WKY are presented in Table 1 . There was no significant difference in age among these 3 groups of animals. LV weight was greater in the SHR-F than in the WKY. RV weight and atrial weight were greater in the SHR-F than in the WKY and SHR-NF. The RV weight was larger in the WKY than in the SHR-NF. LV wet weight normalized by body weight was greater in the SHR groups than in the WKY group. RV and atrial wet weight normalized by BW were greater in the SHR-F group than in the SHR-NF and WKY groups. LV and liver wet/dry ratio were greater in the SHR-F than in the SHR-NF and WKY groups.
Isolated Muscle Mechanics
Mean baseline data for isometric and isotonic contraction parameters are presented in Table 2 . There was no significant difference in cross-sectional area among the groups studied. AT, peak rate of tension development (ϩdT/dt) and decline of tension development (ϪdT/dt), time from peak tension to 50% relaxation (RT 1/2 ) and maximum velocity of isotonic shortening (V max ) were greater in the WKY group than in the SHR-NF and SHR-F groups; there were no differences in these parameters between the SHR-NF and SHR-F. It is possible that the abbreviation in RT 1/2 observed in the SHR-NF and SHR-F relative to WKY may be due in part to the decrease in AT of these preparations. RT and electromechanical (EMD) delay time were not significantly different among the 3 groups. Time to peak tension (TPT) was greater in the SHR-F group than in the WKY and SHR-NF groups. Central segment exponential stiffness constant (K cs ) and , and 10 Ϫ3 mol/L) is shown in Table  3 . There was no increase in AT in the 3 groups at any concentration, and there was no trend for function to increase with time. In the SHR-F at colchicine 10 Ϫ5 mol/L, AT decreased slightly but significantly (PϽ0.05) with time. The effects of 30 minutes of 10 Ϫ4 mol/L colchicine treatment on parameters obtained from isometric contraction, maximum velocity of isotonic shortening, and myocardial stiffness are shown in Table 4 . The drug did not significantly alter any parameter of myocardial function in the 3 groups studied.
␤-Tubulin Assays
Papillary muscle preparations (3 controls, 3 colchicinetreated for 60 minutes) demonstrated an increase in soluble ␤-tubulin in 2 of the 3 colchicine-treated samples. In none of these papillary muscles was an increase in contractile activity observed at any time after the addition of colchicine to the muscle bath. There was no increase in soluble tubulin in the third colchicine-treated muscle. Analysis of 1 control and 1 90-minute colchicine-treated muscle also showed no increase in soluble ␤-tubulin.
Ponceau S staining of the western blot prepared from depolymerized microtubules showed no staining, indicating the failure to extract protein in the depolymerization buffer. The lack of staining was not due to a problem with protein transfer because the protein standards are seen. The reason for the discrepancies between the present data and those of Tagawa et al 22 is unclear but may relate to the amount of the tissue used for the assay. Tagawa and colleagues used 250 mg tissue, which was not possible in the present studies in which each papillary muscle weighed 5 to 10 mg. The increase in soluble tubulin in preparations from 2 hearts in which no improvement in contractile function was found provides some biochemical support to the concept that microtubular depolymerization does not improve contractile dysfunction in failing SHR myocardium.
Discussion
Prior studies have demonstrated a transition from compensated hypertrophy to heart failure in the SHR, with development of impaired muscle function in failing hearts as demonstrated by studies of isolated papillary muscles. 1, [3] [4] [5] 18 The present study investigated the role of colchicine in hypertrophied and failing myocardium from SHR. We examined the hypothesis that microtubular polymerization may participate in the process responsible for myocardial dysfunction in rats with pressure overload and heart failure. If this were the case, myocardial microtubule disruption by colchicine should promote an improvement in the isolated cardiac papillary muscle performance from SHR-F.
The major finding of this study is that there was no improvement in papillary muscle function in SHR-F at any concentration of colchicine studied. The parameters used to evaluate contractile state, relaxation and myocardial stiffness, did not improve in SHR-F after 30 to 90 minutes of exposure to colchicine 10 Ϫ4 mol/L. The AT either did not change or decreased during 30 to 90 minutes of exposure to colchicine. These results suggest that in SHR myocardium the microtubules do not contribute to myocardial dysfunction during the progression from stable hypertrophy to heart failure.
The results of the present study are in accordance with those of Collins et al 14 in the hypertrophied LV from the guinea pig. These investigators infused colchicine to buffer perfused Langendorff preparations to examine the effects of ␤-tubulin depolymerization on myocardial contractility. No improvement in LV systolic function was found in shamoperated or compensated hypertrophied hearts. Rather, developed pressure was depressed with prolonged colchicine perfusion in control and decompensated pressure-overloaded hypertrophied hearts.
On the other hand, other investigators 9 -12 studying myocardial function of the hypertrophied pressure-overloaded RV from the cat found an association between increased microtubular polymerization and contractile dysfunction, with reversibility of dysfunction after microtubule depolymerization by colchicine. Possible reasons for the variability in findings among studies might include species differences, the ventricle studied (left versus right), the method used to produce hypertrophy and preparations used in experiments, and stress levels in the affected ventricle. 23 Tagawa et al 22 have more recently pointed out that in advanced cardiomyopathy, such as is observed in failing SHR myocardium, multiple changes may be responsible for myocardial dysfunction and that it would be unlikely that the state of a single protein such as ␤-tubulin would be responsible for myocardial dysfunction.
Consideration of the dose of colchicine used in this study is of importance. For the studies of Tsutsui et al 9, 10 and Collins et al, 14 the dose of colchicine used was 10 Ϫ6 mol/L. In the studies of Tsutsui et al, 9 ,10 the dose-response curve showed that this dose had a maximum effect on myocyte function. Immunohistochemical analysis of isolated cardiocytes demonstrated a complete absence of microtubules in the cells. Our initial studies revealed no effect of colchicine 10 Ϫ6 mol/L; therefore concentrations of colchicine used in the present study were 10
Ϫ5
, 10
Ϫ4
, and 10 Ϫ3 mol/L. The possibility that the toxic effects of colchicine at higher concentrations may have offset the improvement of myocardial function appears unlikely because the cardiac muscle response was similar at all concentrations of colchicine studied.
The data in this present study also fail to demonstrate that colchicine results in improved intrinsic muscle function in SHR without heart failure. The data show that hypertrophied nonfailing hearts demonstrate depression of contractile function without an increase in muscle stiffness in the baseline state; neither of these parameters are significantly altered by colchicine.
In a prior study, chronic colchicine (1 mg/kg drinking water) was administered in an attempt to prevent contractile depression and heart failure. 15 In that study daily colchicine intake was 60 g/kg, which was 4 times that used in humans. It is difficult to estimate tissue concentration; however, in human myocardium, colchicine may be concentrated from 2 to 20 times more than levels in plasma. 24 At the doses used, it was found that colchicine did not prevent failure.
In contrast to the prior prevention study, 15 colchicine was administered in the present investigation in an attempt to reverse contractile depression, in vitro, in failing myocardium. No evidence of cardiac muscle function improvement was found in SHR-F or SHR-NF after direct exposure to colchicine. Overall, these data fail to suggest that colchicine either prevents or improves contractile dysfunction of hypertrophied myocardium during the transition to heart failure in SHR. Base indicates baseline; Colch, colchicine; K cs , central segment exponential stiffness constant; K wm , whole muscle exponential stiffness constant; V max , maximum velocity of isotonic shortening (muscle length/s). Values are meanϮSD; n indicates number of rats.
